Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1980 1
1994 1
1995 1
1996 1
1999 2
2001 1
2003 2
2004 13
2005 27
2006 16
2007 26
2008 26
2009 18
2010 11
2011 12
2012 17
2013 12
2014 12
2015 24
2016 16
2017 17
2018 17
2019 31
2020 25
2021 43
2022 32
2023 44
2024 49
2025 58
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

519 results

Results by year

Filters applied: . Clear all
Page 1
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR; All ZUMA-7 Investigators and Contributing Kite Members. Locke FL, et al. N Engl J Med. 2022 Feb 17;386(7):640-654. doi: 10.1056/NEJMoa2116133. Epub 2021 Dec 11. N Engl J Med. 2022. PMID: 34891224 Clinical Trial.
BACKGROUND: The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt of first-line chemoimmunotherapy is poor. METHODS: In this international, phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with large B-cell …
BACKGROUND: The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt of first-line chemoim …
A human model of asthma exacerbation reveals transcriptional programs and cell circuits specific to allergic asthma.
Alladina J, Smith NP, Kooistra T, Slowikowski K, Kernin IJ, Deguine J, Keen HL, Manakongtreecheep K, Tantivit J, Rahimi RA, Sheng SL, Nguyen ND, Haring AM, Giacona FL, Hariri LP, Xavier RJ, Luster AD, Villani AC, Cho JL, Medoff BD. Alladina J, et al. Sci Immunol. 2023 May 12;8(83):eabq6352. doi: 10.1126/sciimmunol.abq6352. Epub 2023 May 5. Sci Immunol. 2023. PMID: 37146132 Free PMC article.
Artificial intelligence in nursing: Priorities and opportunities from an international invitational think-tank of the Nursing and Artificial Intelligence Leadership Collaborative.
Ronquillo CE, Peltonen LM, Pruinelli L, Chu CH, Bakken S, Beduschi A, Cato K, Hardiker N, Junger A, Michalowski M, Nyrup R, Rahimi S, Reed DN, Salakoski T, Salanterä S, Walton N, Weber P, Wiegand T, Topaz M. Ronquillo CE, et al. J Adv Nurs. 2021 Sep;77(9):3707-3717. doi: 10.1111/jan.14855. Epub 2021 May 18. J Adv Nurs. 2021. PMID: 34003504 Free PMC article.
Three priorities were identified that need to be addressed in the near future: (a) Nurses must understand the relationship between the data they collect and AI technologies they use; (b) Nurses need to be meaningfully involved in all stages of AI: from development to imple …
Three priorities were identified that need to be addressed in the near future: (a) Nurses must understand the relationship between the data …
The survival of B cells is compromised in kidney disease.
Peroumal D, Jawale CV, Choi W, Rahimi H, Antos D, Li DD, Wang S, Manakkat Vijay GK, Mehta I, West R, Thangaraju M, Nolin TD, Das J, Alcorn JF, Biswas PS. Peroumal D, et al. Nat Commun. 2024 Dec 30;15(1):10842. doi: 10.1038/s41467-024-55187-w. Nat Commun. 2024. PMID: 39738044 Free PMC article.
Using multiple mouse models of kidney disease, we demonstrate that renal dysfunction inhibits germinal center (GC) response against T-dependent antigens. GC B cells exhibit increased apoptosis in kidney disease. Uremic toxin hippuric acid drives loss of mitochondrial membr …
Using multiple mouse models of kidney disease, we demonstrate that renal dysfunction inhibits germinal center (GC) response against T-depend …
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
As compared with placebo, the effects of pemafibrate on lipid levels at 4 months were -26.2% for triglycerides, -25.8% for very-low-density lipoprotein (VLDL) cholesterol, -25.6% for remnant cholesterol (cholesterol transported in triglyceride-rich lipoproteins after lipolysis an …
As compared with placebo, the effects of pemafibrate on lipid levels at 4 months were -26.2% for triglycerides, -25.8% for very-low-density …
The changing spectrum of cardiovascular diseases.
Conrad N, Rahimi K, McMurray JJV, Casadei B. Conrad N, et al. Lancet. 2025 Nov 1;406(10515):2040-2043. doi: 10.1016/S0140-6736(25)00990-0. Epub 2025 Jun 9. Lancet. 2025. PMID: 40505669 No abstract available.
519 results